mantle cell lymphoma

Question 1

clinical course

Answer 1

Variable – in minority some survive untreated for many years, in more patient it is an aggressive NHL variant.

Question 2

general response to treatment

Answer 2

Therapy for MCL is not curative and virtually all patients will have refractory or recurrent disease.

Question 3

therapies

Answer 3

• R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or
• BR (bendamustine plus rituximab).

Question 4

role for RT?

Answer 4

may be helpful on occasion for local disease control in patients with chemotherapy-refractory disease [84,85].

Question 5

Response assessment

Answer 5

PET/CT skull to thigh

Question 6

Defining immunophenotypic feature

Answer 6

cyclinD1 positive

Question 7

Biomarkers with prognostic value in MCL

Answer 7

TP-53
SOX11
Ki-67

Question 8

Induction therapy for transplant candidate

Answer 8

R-CHOP as bridge to autologous HSCT with maintenance rituxan

Question 9

Induction therapy for non transplant candidate

Answer 9

BR vs. R-CHOP with maintenance rituxan

Question 10

Response assessment

Answer 10

CT (studies of PET/CT have yielded mixed results)

Question 11

what differentiates CLL from MCL

Answer 11

CD23 – CLL (positive) from MCL (negative)

Question 12

Favorable IGHV status and SOX 11 status

Answer 12

IGHV mutated
SOX 11 negative